News

January 10, 2020January 10, 2020

Prevalence of Ulcerative Colitis in the US Remains Stable at 1%, Survey Data Show

News

The prevalence of ulcerative colitis remained stable in the United States from 1976 to 2010, affecting 1% of the population, according to a survey analysis. The study also found that ... Read more

January 8, 2020January 8, 2020

People With IBD At Higher Risk Of Serious Viral Infections, Study Suggests

News

Adults with inflammatory bowel disease (IBD) have an increased risk of serious viral infections compared to the general population, a study suggests. This risk was found to be highest among ... Read more

January 6, 2020January 7, 2020

UK Regulatory Agency Approves Launch of Innovation’s Phase 1 Trial of Brilacidin for Ulcerative Colitis

News

The United Kingdom’s Medicines and Healthcare products Regulatory Agency has approved the launch of Innovation Pharmaceuticals’ Phase 1 trial in healthy volunteers to investigate the safety and properties of delayed-release ... Read more

January 3, 2020January 3, 2020

Synedgen Given $259K Grant to Advance Work on Potential IBD Treatments

News

Synedgen will use a $259,000 Congressionally Directed Medical Research Programs (CDMRP) grant to advance work on potential treatments for inflammatory bowel disease (IBD). Specifically, the funds will enable completion of preclinical ... Read more

December 20, 2019December 20, 2019

Vaccine Against Bacterial Protein May Lessen Gut Inflammation, Mouse Study Indicates

News

Vaccinating against flagellin, a protein involved in the movement of certain bacteria, lessened inflammation in the gut, a study of mice shows. These findings suggest that vaccination against certain bacterial ... Read more

December 18, 2019December 18, 2019

FDA Approves Extended-Release Xeljanz for Adults with Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Pfizer‘s extended-release tablets of Xeljanz XR (tofacitinib) to treat adults with moderately to severely active ulcerative colitis. This approval of 11 mg ... Read more

December 16, 2019December 16, 2019

FDA Approves Avsola, Remicade Biosimilar, to Treat Crohn’s Disease and Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Amgen’s Avsola (infliximab-axxq) — a biosimilar to Janssen’s Remicade (infliximab) — to treat adults and children with moderate-to-severe Crohn’s disease (CD) ... Read more

December 12, 2019December 17, 2019

Injection Form of Remicade Biosimilar for IBD Similar to Approved Infusion, Phase 1 Trial Shows

News

A new formulation of CT-P13, a biosimilar of Remicade (infliximab), that is given as an under-the-skin (subcutaneous) injection, was shown to be as safe and effective in treating inflammatory bowel disease ... Read more

December 11, 2019December 11, 2019

Engitix, Morphic Partner to Identify New Ways of Treating Intestinal Fibrosis in IBD Patients

News

Engitix and Morphic Therapeutic announced the start of a research partnership into extracellular matrix targets for treating inflammatory bowel disease (IBD) with intestinal fibrosis, known as fibrostenotic IBD. The extracellular matrix ... Read more

December 6, 2019December 17, 2019

Therapeutic Targeting of MT1-MMP Protein May Help Halt IBD Progression, Study Suggests

News

The membrane type 1-matrix metalloproteinase (MT1-MMP) protein may be a promising therapeutic target for inflammatory bowel disease (IBD) — possibly targeting the disease in its early stages, a study in ... Read more